India, long celebrated as the "pharmacy of the world" for its prowess in manufacturing affordable generic drugs, is now charting an ambitious new course, aiming to transition its pharmaceutical industry towards the high-value domain of biological medicines. This strategic pivot is underpinned by a substantial commitment of ₹10,000 crore (approximately $1.2 billion) under the forthcoming Biopharma SHAKTI scheme, designed to cultivate an end-to-end ecosystem for discovering, developing, and scaling complex biological therapies. This initiative, proposed in the Union Budget 2026-27 and slated for implementation over five years, signals a profound shift in national pharmaceutical policy, moving beyond replication to innovation.
The global biopharmaceutical market is experiencing unprecedented growth, driven by breakthroughs in biotechnology and a rising prevalence of non-communicable diseases such as cancer, autoimmune disorders, and chronic metabolic conditions. Valued at over $400 billion currently, and projected to exceed $800 billion by the end of the decade, the biologics sector represents the cutting edge of medicine. These complex drugs, derived from living organisms, offer targeted therapies with improved efficacy and reduced side effects compared to traditional chemically synthesized medicines. From monoclonal antibodies revolutionizing cancer treatment and immunology, to advanced cell and gene therapies like CAR-T, biologics are addressing previously untreatable conditions and significantly improving patient outcomes worldwide. For India, with its robust pharmaceutical manufacturing base and a growing burden of lifestyle diseases, tapping into this segment is not merely an economic opportunity but a public health imperative.
Despite its dominance in generic drug manufacturing, India has historically lagged in the discovery and development of novel biological entities. The country’s strength has been in biosimilars—highly similar versions of approved biologic drugs—but the infrastructure for foundational research, preclinical testing, and complex clinical trials for innovative biologics has remained nascent. This gap has led to a reliance on expensive external sources for specialized synthetic and structural biology capabilities, as well as for the extensive clinical research needed to bring a new biological drug to market. The Biopharma SHAKTI scheme directly addresses this deficiency, aiming to equip India with the necessary domestic capacity to take biological drug candidates from initial discovery through rigorous testing and large-scale production.
The comprehensive strategy outlined by the Department of Pharmaceuticals involves several critical interventions. A significant focus will be placed on bolstering Contract Research, Development, and Manufacturing Organizations (CRDMOs). These specialized entities are vital for handling the intricate processes involved in biological synthesis, characterization, testing, de-risking, and scaling up drug candidates through preclinical and clinical research phases. Unlike generic chemical synthesis, biologics require highly specialized facilities, expertise in cell culture, fermentation, protein purification, and stringent quality control protocols. By fostering a network of advanced CRDMOs, the government intends to reduce India’s dependence on foreign expertise and infrastructure, offering research grants, establishing shared state-of-the-art facilities, and partnering with state governments to lower input costs such as power and utilities. Manoj Joshi, Secretary of the Department of Pharmaceuticals, highlighted the extensive consultations held with industry, academia, government labs, and research bodies like ICMR, DBT, BIRAC, and NIPER, ensuring the scheme’s guidelines are meticulously tailored to market needs. He emphasized that the focus extends beyond mere manufacturing to the entire development pipeline, acknowledging the significantly greater complexity of developing biological drugs compared to traditional chemical ones.
A cornerstone of the Biopharma SHAKTI initiative is the monumental expansion of India’s clinical trial network. The scheme envisions establishing a network of 1,000 clinical trial centers across the country, a move that would dramatically enhance the availability and efficiency of clinical research facilities. This expansion is crucial for accelerating the clinical development of new biological drugs, which typically undergo lengthy and costly trial phases. Globally, preclinical trials alone can span 2-3 years, and India aims to match these expedited timelines. Furthermore, the integration of electronic health records (EHRs) will streamline data collection, improve trial efficiency, and ensure higher data quality, aligning India’s clinical research capabilities with international best practices. The potential for a large, diverse patient population, combined with relatively lower operational costs, could make India an attractive hub for global clinical trials, contributing to faster drug development for a wider range of conditions.
Beyond infrastructure, the scheme recognizes the transformative potential of emerging technologies. Artificial intelligence (AI) is slated to play a pivotal role in accelerating drug discovery by identifying promising candidates, optimizing molecular structures, and predicting potential toxicities, thereby significantly shortening the initial phases of drug development. However, as Joshi noted, while AI can pinpoint potential molecules, specialized CRDMOs remain indispensable for producing test batches, conducting animal safety studies, and scaling molecules for human trials. The government is committed to building a broader innovation ecosystem, bringing together large pharmaceutical companies, nimble startups, specialized CRDMOs, and AI companies to foster a collaborative environment conducive to cutting-edge research and rapid development.
The economic implications of this strategic shift are profound. India’s current biopharma market, valued at approximately $64.5 billion according to the India Brand Equity Foundation, is poised for significant expansion. The government has set an ambitious target of capturing a 5% share of the global biopharmaceutical market. Achieving this would not only generate substantial export revenues but also create a vast number of high-skilled jobs in research, development, manufacturing, and clinical operations, diversifying the nation’s economic output. Moreover, the domestic production of biologics is expected to drastically reduce treatment costs for patients. Dr. SK Poddar, a consultant surgeon and president-elect of the Delhi Medical Association, highlighted that imported biologics for serious diseases like cancer are often prohibitively expensive, making them inaccessible to the majority of Indian patients. Local production by multiple domestic players is anticipated to drive down prices, making life-saving therapies available to a much broader population, including those in smaller towns and villages. This aligns with India’s "Make in India" and "Atmanirbhar Bharat" (self-reliant India) initiatives, bolstering national health security and reducing reliance on foreign pharmaceutical supplies.
However, the path to becoming a global biologics powerhouse is fraught with challenges. India will face intense competition from established global biopharma giants in the US, Europe, and increasingly, China, which has also made significant investments in its biopharmaceutical sector. Navigating the complex landscape of intellectual property rights, ensuring robust patent protection for novel discoveries, and adhering to stringent global regulatory standards will be critical. The sheer cost and lengthy timelines associated with biologics development—often spanning a decade and costing billions of dollars per successful drug—mean that sustained funding, beyond the initial ₹10,000 crore, and unwavering commitment will be essential. Shreehas Tambe, CEO and MD of Biocon Ltd., a pioneering Indian biopharmaceutical company, welcomed the scheme, acknowledging that it addresses crucial gaps across the entire biologics and biosimilars value chain, from pipeline expansion and clinical trials to regulatory improvement and workforce skill development. He affirmed Biocon’s commitment to contributing to a globally competitive, innovation-led biopharma sector in India.
Ultimately, India’s investment in Biopharma SHAKTI represents a calculated and forward-looking gamble. It is a recognition that the future of medicine lies in complex, high-value biological therapies and that India must evolve beyond its generic strengths to secure a leading position in this transformative domain. By fostering an environment of innovation, strengthening research infrastructure, streamlining regulatory processes, and developing a skilled workforce, India aims not just to meet domestic healthcare needs but to emerge as a formidable force in the global biopharmaceutical landscape, driving both economic prosperity and improved health outcomes worldwide. The journey will be long and arduous, but the potential rewards—both for India and global health—are immense.
